NCT04481607View on ClinicalTrials.gov

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

PHASE1UnknownINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Advanced Solid Tumor or Hematologic Tumor
Interventions
DRUG

TQB3454

TQB3454 tablets is a small molecule oral drug.

Trial Locations (5)

100089

RECRUITING

Beijing Cancer Hospital, Beijing

221000

RECRUITING

The Affiliated Hosptial of Xuzhou Medical University, Xuzhou

300020

RECRUITING

Tianjing Medical University Cancer Institute&Hospital, Tianjin

300041

RECRUITING

Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin

311100

RECRUITING

The First Affiliated Hosptial Zhejiang University School of Medical, Hangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY